PeptidePedia The community reference

Special:RecentChanges

Change log·7,183 revisions·page 11 of 72

Every change to PeptidePedia Wiki, newest first. N marks a new page, m a minor edit and b an edit by an approved bot. The byte figure is the page size after the edit; the coloured figure is the change. 7,183 changes are logged in total.

7,183Logged changes
598Bot edits
175Page creations
256Active editors

26 April 2026

  1. (diff | hist) 11:24 AmbioPharm 17,173 +220 PrimarySrcPatia (talk | contribs) add the note that self-published material is usable only for what it states about itself [rollback]
  2. (diff | hist) m 10:38 Test report forgery 5,391 ±0 Chromatokid (talk | contribs) correct the description of the sampling procedure [rollback]
  3. (diff | hist) 10:25 Talk:Triple agonist 537 +143 RetatrutideRuben (talk | contribs) /* Predicted failure mode */ new section
  4. (diff | hist) 10:22 Talk:Exenatide 674 +153 SiteReactionSuz (talk | contribs) /* Microsphere nodules */ new section
  5. (diff | hist) 09:00 Subcutaneous injection 5,293 ±0 BUD_Bertram (talk | contribs) add the shelf life after first puncture, attributed [rollback]
  6. (diff | hist) 06:44 Glucagon-like peptide-1 12,294 ±0 EmptyingElke (talk | contribs) add the cleavage site by residue number [rollback]
  7. (diff | hist) m 03:00 Xi'an Mokemei Biotechnology 15,421 ±0 SecondarySrc_Seb (talk | contribs) add the storage and handling guidance the organisation publishes [rollback]
  8. (diff | hist) 02:07 Area percent purity 8,537 ±0 PeakShapePol (talk | contribs) state the titration endpoint and the reagent factor [rollback]

25 April 2026

  1. (diff | hist) m 23:38 Fmoc chemistry 4,618 ±0 ColdChainCleo (talk | contribs) add the light-exposure point for photosensitive material [rollback]
  2. (diff | hist) 20:48 Limit of detection 4,865 ±0 DiluentDiya (talk | contribs) ce [rollback]
  3. (diff | hist) 19:39 VendorInvestigate 5,067 ±0 ForgeryFinder (talk | contribs) expand §What documentary review examines [rollback]
  4. (diff | hist) 14:00 Talk:Bacteriostatic water 748 +120 PrimarySrcPatia (talk | contribs) /* Preservative-induced aggregation */ reply
  5. (diff | hist) 12:06 Good manufacturing practice 5,123 ±0 UnitsUrsula (talk | contribs) convert the jurisdiction comparison to a table [rollback]
  6. (diff | hist) 10:31 Zhuhai Kerui Biotechnology 14,711 ±0 B12_Bettina (talk | contribs) expand §Corporate identity and history [rollback]
  7. (diff | hist) 10:30 Talk:Bacteriostatic water 537 +183 StabilityStig (talk | contribs) /* Preservative-induced aggregation */ new section
  8. (diff | hist) 09:12 Talk:Insulin secretion 959 +101 HedgeHedda (talk | contribs) /* Beta-cell mass at diagnosis: the number keeps changing */ reply
  9. (diff | hist) m b 06:44 Body composition assessment 5,029 ±0 ArchiveBot (talk | contribs) bot: sort category members [rollback]
  10. (diff | hist) m b 05:24 Hypoglycaemia 4,473 ±0 StubSorterBot (talk | contribs) bot: flag bare reference [rollback]
  11. (diff | hist) m 02:26 Syringe dead space 20,968 ±0 Chromatokid (talk | contribs) add a second worked example at a different vial strength [rollback]

24 April 2026

  1. (diff | hist) m 23:32 Lot traceability 5,317 ±0 TitrationTheo (talk | contribs) add the chain-of-custody point to §Limitations [rollback]
  2. (diff | hist) 20:46 Peptide 6,813 ±0 CounterfeitCato (talk | contribs) give the vial sizes in millilitres of nominal capacity [rollback]
  3. (diff | hist) m 20:24 Drug master file 4,325 ±0 CDMO_Caradoc (talk | contribs) rm the claim that the position has changed; no source supports it [rollback]
  4. (diff | hist) 16:40 Talk:Insulin secretion 748 +175 BetaCellBoyd (talk | contribs) /* Beta-cell mass at diagnosis: the number keeps changing */ reply
  5. (diff | hist) 14:00 Talk:Reverse-phase HPLC 748 +132 Retention_Time_Rae (talk | contribs) /* Column temperature omission */ reply
  6. (diff | hist) 13:55 Talk:Weight regain after discontinuation 748 +94 ITT_Imelda (talk | contribs) /* Why withdrawal design is needed */ reply
  7. (diff | hist) 13:05 Talk:Insulin secretion 537 +258 CitationChaser (talk | contribs) /* Beta-cell mass at diagnosis: the number keeps changing */ new section
  8. (diff | hist) 11:05 Talk:Lyophilisation 1,507 +171 ScopeSeverin (talk | contribs) /* Section on unregulated ambient shipping — is it in scope here? */ reply
  9. (diff | hist) 10:20 Talk:Reverse-phase HPLC 537 +154 ColumnOvenCoy (talk | contribs) /* Column temperature omission */ new section
  10. (diff | hist) 10:20 Talk:Weight regain after discontinuation 537 +145 PreregPriya (talk | contribs) /* Why withdrawal design is needed */ new section
  11. (diff | hist) 10:08 Talk:Peptide stability table 1,518 +249 RfC_Rasmus (talk | contribs) /* RfC: should the table give a −20 °C default for research powders? */ reply
  12. (diff | hist) 07:24 Repackaging 4,759 ±0 TB500_Tarquin (talk | contribs) expand §Why the record is the whole thing [rollback]
  13. (diff | hist) m 00:37 Sangon Biotech 14,764 ±0 PrimarySrcPatia (talk | contribs) label the reception tally as weak, self-selected evidence at this point of use [rollback]

23 April 2026

  1. (diff | hist) 23:57 Amylin receptor agonist 5,245 ±0 Chromatokid (talk | contribs) correct the dose ladder — the maintenance dose is not the maximum dose [rollback]
  2. (diff | hist) 23:45 Liraglutide 5,967 ±0 GramsNotUnitsGil (talk | contribs) reorder the analogues chronologically rather than alphabetically [rollback]
  3. (diff | hist) 22:32 Baseline laboratory panel 4,429 ±0 PanelPlannerPam (talk | contribs) clarify that the units differ between the two cited papers [rollback]
  4. (diff | hist) m 13:30 Peptide synthesis 5,649 ±0 FreightFenna (talk | contribs) add the reconstitution-stability sentence with its storage condition [rollback]
  5. (diff | hist) 09:02 Guangzhou JEEP Biotechnology 15,452 ±0 Ref_Desk_Ron (talk | contribs) expand §Notability and coverage [rollback]
  6. (diff | hist) 03:57 Dual incretin agonist 5,851 ±0 MolarMassMaeve (talk | contribs) give the INN alongside the trade name at first mention [rollback]
  7. (diff | hist) 02:29 Dose escalation schedule 4,993 ±0 ArcuateArt (talk | contribs) state that swirling rather than shaking is the handling convention, sourced [rollback]
  8. (diff | hist) m 02:23 Melanotan II 4,649 ±0 TesamorelinTeg (talk | contribs) add the parent protein and the residue range the fragment spans [rollback]
  9. (diff | hist) m b 00:25 Regulatory status by jurisdiction 4,444 ±0 ArchiveBot (talk | contribs) bot: sort category members [rollback]

22 April 2026

  1. (diff | hist) 14:20 Talk:Underfilling 748 +125 StopperingSteff (talk | contribs) /* Overage section balances the article */ reply
  2. (diff | hist) m b 13:51 Vial 26,012 ±0 CiteBot (talk | contribs) bot: sort category members [rollback]
  3. (diff | hist) 13:50 Talk:Cold-chain freight 748 +145 ChainCustodyChad (talk | contribs) /* Robustness of the dry solid */ reply
  4. (diff | hist) m 12:04 Semaglutide 10,355 ±0 TimelineTiernan (talk | contribs) give the strength per pen as well as per millilitre [rollback]
  5. (diff | hist) 10:50 Talk:Underfilling 537 +169 BalanceBirdie (talk | contribs) /* Overage section balances the article */ new section
  6. (diff | hist) 10:15 Talk:Cold-chain freight 537 +155 StabilityStig (talk | contribs) /* Robustness of the dry solid */ new section
  7. (diff | hist) 09:06 Patent expiry and biosimilars 4,553 ±0 AppendixAlva (talk | contribs) rm the claim that the position has changed; no source supports it [rollback]
  8. (diff | hist) 08:47 Talk:Lyophilisation 1,296 +269 FreightFenna (talk | contribs) /* Section on unregulated ambient shipping — is it in scope here? */ reply

21 April 2026

  1. (diff | hist) m 23:01 Peptide content 8,404 ±0 CouplingCillian (talk | contribs) add the detection wavelength [rollback]
  2. (diff | hist) m 22:48 Sarcopenia 4,491 ±0 Chromatokid (talk | contribs) correct the reference interval — the source gives it for fasting samples [rollback]
  3. (diff | hist) 19:02 Vial filling and stoppering 4,833 ±0 LipidLedgerLou (talk | contribs) rm the blanket claim that excursions are harmless [rollback]
  4. (diff | hist) 18:59 Karl Fischer titration 9,318 ±0 StabilityStig (talk | contribs) add the system-suitability criteria the method actually specifies [rollback]
  5. (diff | hist) 16:32 Wuhan Wansheng Biotechnology 15,849 ±0 ForgeryFinder (talk | contribs) correct the other-designations row — those are trading variants, not subsidiaries [rollback]
  6. (diff | hist) 16:17 Third-party testing 7,489 ±0 RedirectRini (talk | contribs) state the method the reporting service uses, since it is not the only one available [rollback]
  7. (diff | hist) 15:30 Talk:Lyophilisation 1,085 +310 ScopeSeverin (talk | contribs) /* Section on unregulated ambient shipping — is it in scope here? */ new section
  8. (diff | hist) 14:25 SURPASS trial programme 5,078 ±0 StubTagTeodor (talk | contribs) add the PMID [rollback]
  9. (diff | hist) 14:10 Talk:Survodutide 611 +161 SurvodutideSaff (talk | contribs) /* Histological endpoints caveat */ reply
  10. (diff | hist) 13:55 Talk:STEP trial programme 748 +185 EndpointEnid (talk | contribs) /* Estimands */ reply
  11. (diff | hist) 10:40 Talk:Survodutide 400 +180 EndpointEnid (talk | contribs) /* Histological endpoints caveat */ new section
  12. (diff | hist) 10:20 Talk:STEP trial programme 537 +165 ITT_Imelda (talk | contribs) /* Estimands */ new section
  13. (diff | hist) 01:40 Hunan Aslsen Technology 15,492 ±0 CouplingCillian (talk | contribs) add the how-to-request-a-batch-record sentence to §Ordering and availability [rollback]

20 April 2026

  1. (diff | hist) 19:55 USP General Chapter 71 4,657 ±0 DrTitration (talk | contribs) copyedit [rollback]
  2. (diff | hist) 16:40 Peptide harm reduction 4,800 ±0 ColumnOvenCoy (talk | contribs) fix the anchor on an internal link [rollback]
  3. (diff | hist) 13:55 Talk:Melanotan II 748 +116 MelanocortinMil (talk | contribs) /* Non-selectivity as the theme */ reply
  4. (diff | hist) m 11:59 Shenzhen Hybio Pharmaceutical 17,716 +220 BacWaterBarnaby (talk | contribs) add the registered legal name exactly as it appears in the registry record [rollback]
  5. (diff | hist) 10:20 Talk:Melanotan II 537 +169 ReceptorRhoda (talk | contribs) /* Non-selectivity as the theme */ new section
  6. (diff | hist) m 10:00 Analytical method validation 5,342 ±0 TFA_Counterion (talk | contribs) expand §Specificity for peptides [rollback]
  7. (diff | hist) 09:48 Talk:Karl Fischer titration 1,233 +137 Ref_Desk_Ron (talk | contribs) /* Should the mass-balance table give ranges or single figures? */ reply
  8. (diff | hist) m b 09:44 Reconstitution of lyophilised peptides 5,761 ±0 CiteBot (talk | contribs) bot: repair redlinked category [rollback]

19 April 2026

  1. (diff | hist) 21:46 GenScript Peptides 17,833 ±0 EndotoxinEd (talk | contribs) rm the adjective — an organisation article describes, it does not praise [rollback]
  2. (diff | hist) 21:34 Bacterial endotoxin test 5,317 ±0 SemaxSevi (talk | contribs) add the system-suitability criteria the method actually specifies [rollback]
  3. (diff | hist) 14:33 Talk:Proglucagon 748 +171 ScopeSeverin (talk | contribs) /* Assay cross-reactivity deserves its own article */ reply
  4. (diff | hist) 13:54 GLP-1 receptor 7,570 ±0 Hedgerow_Hal (talk | contribs) give the fasting and postprandial concentrations with the assay named [rollback]
  5. (diff | hist) 13:15 Talk:Dose escalation schedule 748 +179 TitrationTheo (talk | contribs) /* Schedule table is descriptive */ reply
  6. (diff | hist) 11:30 Talk:Cold chain 2,214 +381 Ref_Desk_Ron (talk | contribs) /* RfC: should this article cover consumer shipping practice? */ reply
  7. (diff | hist) 11:07 Talk:Proglucagon 537 +122 AnalyticalAnnie (talk | contribs) /* Assay cross-reactivity deserves its own article */ new section
  8. (diff | hist) 09:30 Talk:Dose escalation schedule 537 +170 NPOV_Nadia (talk | contribs) /* Schedule table is descriptive */ new section
  9. (diff | hist) m 06:38 SinoPep 18,360 ±0 EndotoxinEd (talk | contribs) add the outbound storefront link, marked nofollow and sponsored per the external-links convention [rollback]
  10. (diff | hist) 06:12 Cagrilintide 4,256 ±0 AnalyticalAnnie (talk | contribs) expand §Reported findings [rollback]
  11. (diff | hist) m 02:43 Exenatide 5,754 ±0 MolarMassMaeve (talk | contribs) convert the substitution list to a table so the analogues line up [rollback]
  12. (diff | hist) 02:27 Shanghai Wibson Biotechnology 15,440 ±0 AnalyticalAnnie (talk | contribs) ce [rollback]
  13. (diff | hist) 00:35 Crude peptide 4,775 ±0 NewLabNell (talk | contribs) add the stopper material, since it affects moisture ingress [rollback]

18 April 2026

  1. (diff | hist) 16:22 Certificate of analysis 10,014 ±0 AxisLabelAgda (talk | contribs) consistent en dashes in ranges [rollback]
  2. (diff | hist) 16:11 Hubei Jianxiang Bioscience 14,855 ±0 ArchiveAudit (talk | contribs) add category for suppliers in China [rollback]
  3. (diff | hist) 15:29 Reverse-phase HPLC 5,499 ±0 DataTableDunja (talk | contribs) convert the method-comparison paragraph to a table [rollback]
  4. (diff | hist) 14:55 Reference standard 5,217 ±0 GroupBuyGalen (talk | contribs) add the peptide-content point: area percent alone cannot give a mass [rollback]
  5. (diff | hist) 14:00 Talk:Janoshik Analytical 748 +164 PeakShapePol (talk | contribs) /* Chromatogram-reading table */ reply
  6. (diff | hist) 12:31 Talk:Karl Fischer titration 1,022 +178 AnalyticalAnnie (talk | contribs) /* Should the mass-balance table give ranges or single figures? */ reply
  7. (diff | hist) 11:33 Talk:Peptide stability table 1,307 +246 PuffRemoverPax (talk | contribs) /* RfC: should the table give a −20 °C default for research powders? */ reply
  8. (diff | hist) 10:35 Talk:Janoshik Analytical 537 +200 Chromatokid (talk | contribs) /* Chromatogram-reading table */ new section
  9. (diff | hist) 10:15 HOMA-IR 4,511 ±0 MOTSc_Mira (talk | contribs) add the pre-analytical requirement: tube type and time to separation [rollback]
  10. (diff | hist) 10:05 Talk:Global access disparity 1,033 +175 ScopeSeverin (talk | contribs) /* Framing of the access argument */ reply
  11. (diff | hist) 10:02 Talk:Karl Fischer titration 811 +209 PlainNumbersPip (talk | contribs) /* Should the mass-balance table give ranges or single figures? */ new section
  12. (diff | hist) 09:28 Batch number 4,573 ±0 Peptide_Pete (talk | contribs) expand §Assignment [rollback]

17 April 2026

  1. (diff | hist) 20:41 SURMOUNT trial programme 5,021 ±0 SurrogateSunday (talk | contribs) the trial was open-label; the article implied blinding [rollback]
  2. (diff | hist) 14:10 Talk:Insulin syringe 748 +112 DeadSpaceDot (talk | contribs) /* Percentage-of-full-scale accuracy */ reply
  3. (diff | hist) m 11:49 Customs seizure 4,785 ±0 API_Aurora (talk | contribs) add the pharmacopoeial chapter reference [rollback]
  4. (diff | hist) 11:34 Talk:Beyond-use date 1,581 +163 ScopeSeverin (talk | contribs) /* Community dating practice: describe or omit? */ reply
  5. (diff | hist) 10:35 Talk:Insulin syringe 537 +155 SyringeSybille (talk | contribs) /* Percentage-of-full-scale accuracy */ new section